文献速递胸部肿瘤放疗

社会经济贫困人群中III期非小细胞肺癌在度伐利尤单抗时代的真实世界结局

Real-world outcomes of stage III non-small cell lung cancer in the durvalumab era: insights from a socioeconomically deprived population.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-07-10

该回顾性队列纳入2017至2022年接受根治性放化疗的656例III期不可切除非小细胞肺癌患者,其中62%居住于最贫困的社会经济五分位区。

要点

  • 55%起始度伐利尤单抗者未能完成全年治疗,但53%早期停药者2年仍无病。
  • 单纯放疗占59%且2年OS和PFS最差,与贫困或CCI无关,提示决策与客观体能不匹配。

核心结论

  • 在可接受同步放化疗的患者中,度伐利尤单抗巩固的无进展生存获益在真实世界贫困共病人群中得到重复。
  • 高比例患者仅接受单纯根治性放疗且生存较差,该现象不能由社会经济贫困或共病客观指标解释,提示临床决策与客观体能评估存在不匹配。

研究设计与样本

  • 回顾性观察性队列研究,纳入2017年1月1日至2022年12月31日接受根治性(放)化疗的III期不可切除非小细胞肺癌患者共656例。
  • 按治疗分组比较结局:单纯放疗、序贯放化疗、同步放化疗、同步放化疗后度伐利尤单抗巩固,并采用多因素Cox比例风险回归分析相关因素。

主要发现

  • 中位年龄69岁,54%为男性,81%体能状态评分为0或1,中位Charlson共病指数3(2–5),62%居住于最贫困社会经济五分位区。
  • 单纯放疗为最常见治疗(59%),其选择似乎受年龄较大和体能状态较高影响,而非贫困或Charlson共病指数。
  • 单纯放疗组2年总生存和无进展生存最差,且独立于其他混杂因素。
  • 起始度伐利尤单抗者中55%未能完成全年治疗,但早期停药者中53%在2年时仍无病。

关键数值与推荐

  • 反射性生物标志物检测随时间改善,序贯放化疗使用下降,同步放化疗(含或不含度伐利尤单抗)比例上升。

临床怎么用

  • 对能耐受同步放化疗的III期不可切除非小细胞肺癌患者,应考虑度伐利尤单抗巩固以改善无进展生存。
  • 不应仅凭社会经济贫困或Charlson共病指数排除根治性同步放化疗,需结合客观体能评估优化决策。
  • 度伐利尤单抗全年完成率有限,早期停药后部分患者仍可维持无病,需个体化管理治疗时长。

局限性

  • 回顾性观察性设计可能存在选择偏倚和混杂。
  • 单中心或区域人群的社会经济贫困特征可能限制外推性。
  • 未报告度伐利尤单抗停药原因及具体毒性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The introduction of consolidation durvalumab after chemoradiotherapy (CRT) for unresectable stage 3 non-small cell lung cancer (NSCLC), as established by the PACIFIC trial, has transformed survival outcomes. However, its impact remains uncertain in populations characterised by high levels of socioeconomic deprivation, multimorbidity, and historically poorer cancer outcomes compared to other regions. MATERIALS/METHODS: This retrospective observational cohort study included all patients with stage III unresectable NSCLC who received radical (chemo)radiotherapy, between 01/01/2017 - 31/12/2022. Clinical outcomes were compared across treatment groups: radiotherapy alone, sequential CRT, concurrent CRT, and concurrent CRT followed by consolidation durvalumab. Multivariate Cox proportional hazards regression was employed to identify factors associated with outcomes. RESULTS: 656 patients with stage III NSCLC treated with radical radiotherapy were included. The median age was 69 years, and 54% were male. Most patients had a PS of 0 or 1 (81%), the median Charlson Comorbidity Index (CCI) was 3 (2 - 5) and 62% resided in the most deprived socioeconomic quintiles. Radiotherapy alone was the most common treatment (59%). Administration of radiotherapy alone appeared to be influenced by older age and higher performance status, and not by deprivation or objective functional measurements of multimorbidity (i.e. CCI). Reflex biomarker testing improved over time, while the use of sequential CRT declined, and the rates of concurrent CRT, with or without durvalumab, increased.Multivariate regression demonstrated that patients receiving concurrent CRT plus durvalumab achieved superior 2 year progression-free survival (PFS) compared with concurrent CRT alone (HR 0.51, 0.33 - 0.78, p=0.002). Patients treated with radiotherapy alone had the poorest 2-year OS and PFS, independent of other confounders. Delivering a full year of durvalumab was challenging, with 55% of patients who started durvalumab being unable to complete treatment. However, 53% of those who discontinued durvalumab early remained disease-free at 2 years. CONCLUSION: This study reinforces the progression-free survival benefit of consolidation durvalumab in patients able to undergo concurrent CRT within a large real-world cohort. Although the cohort was socially deprived and comorbid, the high proportion of patients receiving radical radiotherapy alone, and their associated poorer survival outcomes, were not explained by this, revealing a mismatch between objective fitness and clinical decision making, The associated poorer survival outcomes from radiotherapy alone highlights the urgent need to optimise treatment strategies for such patients.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Peters AL, Stubbs HD, Duncan SF, et al. Real-world outcomes of stage III non-small cell lung cancer in the durvalumab era: insights from a socioeconomically deprived population. Clin Transl Radiat Oncol. 2026. PMID: 42502457. doi:10.1016/j.ctro.2026.101232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。